
News|Articles|July 1, 2003
Pharmaceutical marketing practices and generic drugs in the spotlight
Author(s)Jill Wechsler
Formulary committees, pharmacy benefit managers (PBMs), pharmacists, and physicians face increased scrutiny of their relationships with pharmaceutical manufacturers under a final fraud policy statement from the Office of the Inspector General (OIG) of the Department of Health and Human Services (HHS).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
Atopic dermatitis care advances in 2025 with new biologics, topicals and oral therapies
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
UC Davis develops new drug for bladder cancer patients
5


















































